Daniel V. Catenacci, MD, University of Chicago

Applying Data to the Real World in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Emerging Approaches in HER2+ Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

VEGFR TKIs in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Maintenance Therapy in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Adjuvant Treatment in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Looking Toward the Future in Gastroesophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Toxicity Management in Second Line for Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Clinical Rationale for Antiangiogenics in Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Predicting Response With Biomarkers in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Applying New Data in the Real-World for GEJ Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

ESMO 2020: Practice-Changing Data in Esophageal Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

First-Line I/O Successful in Gastric Adenocarcinoma

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Frontline Treatment in Metastatic Gastric Cancer

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Optimal Approach Toward Advanced Gastric Cancers in US

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Global Trends in Gastric Cancers

ByJohanna Bendell, MD, Sarah Cannon Cancer Institute,Daniel V. Catenacci, MD, University of Chicago,Ian Chau, MD, Royal Marsden Hospital,Yelena Y. Janjigian, MD, Memorial Sloan Kettering Cancer Center,Ken Kato, MD, PhD, National Cancer Center Hospital East

October 22nd 2020

Metastatic Gastric Cancer: Recent Advances and Future Directions

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Perioperative Strategies in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Later-Line Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Second-Line Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Novel Agents Targeting FGF

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Promising Frontline Trials

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Emerging Biomarkers in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Later Lines of Therapy in Metastatic Gastric Cancer

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Global Use of Second-Line Therapy in mGC

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Metastatic Gastric Cancer: Identifying Disease Progression

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Gastric Cancer: Global Perspectives on Maintenance Therapy

BySalah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center,Daniel V. Catenacci, MD, University of Chicago,David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center,Kei Muro, MD, Aichi Cancer Center Hospital

June 1st 2020

Articles by Daniel V. Catenacci, MD, University of Chicago

Applying Data to the Real World in Gastric Cancer

Emerging Approaches in HER2+ Gastric Cancers

VEGFR TKIs in Gastroesophageal Cancer

Maintenance Therapy in Gastric Cancers

Adjuvant Treatment in Gastroesophageal Cancer

Looking Toward the Future in Gastroesophageal Cancer

Toxicity Management in Second Line for Gastric Cancer

Clinical Rationale for Antiangiogenics in Gastric Cancer

Predicting Response With Biomarkers in Gastric Cancers

Applying New Data in the Real-World for GEJ Cancer

ESMO 2020: Practice-Changing Data in Esophageal Cancer

First-Line I/O Successful in Gastric Adenocarcinoma

Treatment Landscape in Gastric Cancers Pre-ESMO 2020

Frontline Treatment in Metastatic Gastric Cancer

Optimal Approach Toward Advanced Gastric Cancers in US

Global Trends in Gastric Cancers

Metastatic Gastric Cancer: Recent Advances and Future Directions

Perioperative Strategies in Metastatic Gastric Cancer

Metastatic Gastric Cancer: Promising Later-Line Trials

Metastatic Gastric Cancer: Promising Second-Line Trials

Metastatic Gastric Cancer: Novel Agents Targeting FGF

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

Metastatic Gastric Cancer: Promising Frontline Trials

Emerging Biomarkers in Metastatic Gastric Cancer

Later Lines of Therapy in Metastatic Gastric Cancer

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

Global Use of Second-Line Therapy in mGC

Metastatic Gastric Cancer: Identifying Disease Progression

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

Gastric Cancer: Global Perspectives on Maintenance Therapy

Latest Updated Articles

Trending on OncLive

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma

European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

FDA Approval of Perioperative EV/Pembrolizumab Reshapes MIBC Treatment Paradigm